Antonio Llombart-Cussac

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Antonio Llombart-Cussac

Mar 11, 2025, 06:08 | Blog

Aleix Prat: The prospective real-world clinical impact of HER2DX

Aleix Prat, Director of the Clinic Barcelona Comprehensive Cancer Center, shared a post on LinkedIn…

Jan 9, 2025, 16:38 | Blog

Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Paolo Tarantino shared on X: "The DEBBRAH trial cohort 5 is published on Med by…

Dec 12, 2024, 16:50 | Insight

Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer

Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…

Dec 12, 2024, 13:36 | Blog

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Erika Hamilton, The Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on…

Nov 13, 2024, 08:27 | Insight

Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent…

All: 5 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023